What changed in Biogen Inc.'s latest annual report
In the year ended 31 Dec 2025, Biogen Inc.'s revenue rose 2.2% to USD 9.89bn, from USD 9.68bn; net income fell 20.8% to USD 1.29bn, from USD 1.63bn; total assets rose 5% to USD 29.44bn, from USD 28.05bn.
Year ended 31 Dec 2025. Source: 10-K filed 6 Feb 2026, read it on SEC EDGAR.
USD 9.68bn to USD 9.89bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 9.68bn | 9.89bn | Up 2.2% |
| Net income | 1.63bn | 1.29bn | Down 20.8% |
| Total assets | 28.05bn | 29.44bn | Up 5% |
| Total liabilities | 11.33bn | 11.18bn | Down 1.3% |
| Long-term debt | 6.30bn | 6.29bn | Down 0.1% |
Questions people ask
Did Biogen Inc.'s revenue grow last year?
Revenue grew 2.2%, from USD 9.68bn to USD 9.89bn in the year ended 31 Dec 2025.
Is Biogen Inc. profitable?
Yes. Net income was USD 1.29bn in the year ended 31 Dec 2025. The year before: USD 1.63bn.
How much cash and debt does Biogen Inc. have?
At its latest year end (31 Dec 2025), Biogen Inc. reported long-term debt of USD 6.29bn.
Where do these numbers come from?
From Biogen Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Biogen Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%
- Repligen CorpCash and cash equivalents down 25.3%